Survival rates among breast cancer patients have nothing to do with whether a woman inherits any of the best-known defective genes, according to new research. The study was conducted in part to determine if women with BRCA1 or BRCA2 gene mutations should receive different treatment from those who lack the defective genes.

Related Summaries